Search research articles
Contact Us
Filters
Showing results (111-120 of 137) with videos related to
Page
of 14
Sort By:
Journal of the American Academy of Dermatology
|
June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Annals of the Rheumatic Diseases
|
September 15, 2012
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
Carrie L Wagner, Sudha Visvanathan, Michael Elashoff, et al.
Clinical, Cosmetic and Investigational Dermatology
|
August 5, 2022
Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group
Abdullah Alakeel, Afaf Al Sheikh, Ali A Alraddadi, et al.
The British Journal of Dermatology
|
December 17, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
John E Harris, Kim Papp, Khaled Ezzedine, et al.
Journal of Cutaneous Medicine and Surgery
|
November 9, 2016
Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF)
Afsaneh Alavi, David N Adam, Ra'ed Alhusayen, et al.
American Journal of Clinical Dermatology
|
May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Lawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.
The Journal of Dermatological Treatment
|
August 9, 2021
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis
Kim Papp, Zygmunt Adamski, Lyn Guenther, et al.
The British Journal of Dermatology
|
December 26, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
John E Harris, Kim Papp, Khaled Ezzedine, et al.
Annals of the Rheumatic Diseases
|
December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
JAMA Dermatology
|
August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
April W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 137) with videos related to
Sort By:
Page
of 14
Journal of the American Academy of Dermatology
|
June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Annals of the Rheumatic Diseases
|
September 15, 2012
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
Carrie L Wagner, Sudha Visvanathan, Michael Elashoff, et al.
Clinical, Cosmetic and Investigational Dermatology
|
August 5, 2022
Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group
Abdullah Alakeel, Afaf Al Sheikh, Ali A Alraddadi, et al.
The British Journal of Dermatology
|
December 17, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
John E Harris, Kim Papp, Khaled Ezzedine, et al.
Journal of Cutaneous Medicine and Surgery
|
November 9, 2016
Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF)
Afsaneh Alavi, David N Adam, Ra'ed Alhusayen, et al.
American Journal of Clinical Dermatology
|
May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Lawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.
The Journal of Dermatological Treatment
|
August 9, 2021
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis
Kim Papp, Zygmunt Adamski, Lyn Guenther, et al.
The British Journal of Dermatology
|
December 26, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study
John E Harris, Kim Papp, Khaled Ezzedine, et al.
Annals of the Rheumatic Diseases
|
December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
JAMA Dermatology
|
August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
April W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Page
of 14